SEATTLE, April 7, 2014 /PRNewswire/ -- Omeros
Corporation (NASDAQ: OMER), a biopharmaceutical company committed
to discovering, developing and commercializing products focused on
inflammation, bleeding and disorders of the central nervous system,
today announced that Gregory A.
Demopulos, M.D., chairman and chief executive officer, will
present at the 13th Annual Needham Healthcare Conference
in New York later this week.
The presentation is scheduled for Wednesday,
April 9, 2014 at 3:00 p.m.
EDT.
The presentation will be webcast. The live and archived webcasts
can be accessed on the "Events" page of the Company's website at
www.omeros.com.
About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed
to discovering, developing and commercializing small-molecule and
protein therapeutics targeting inflammation, coagulopathies and
disorders of the central nervous system. Derived from its
proprietary PharmacoSurgery® platform, the Company's
lead drug product, Omidria™ (OMS302) for lens
replacement surgery, is currently under review for marketing
approval by both the US Food and Drug Administration and the
European Medicines Agency with US commercial launch planned for the
second half of 2014. Omeros' six other clinical programs are
focused on schizophrenia, Huntington's disease and cognitive
impairment; addictive and compulsive disorders; complement-related
diseases; and preventing problems associated with surgical
procedures. Omeros also has a proprietary GPCR platform, which is
making available an unprecedented number of new GPCR drug targets
and corresponding compounds to the pharmaceutical industry for drug
development.
SOURCE Omeros Corporation